Trial Profile
A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2007
Price :
$35
*
At a glance
- Drugs Elsamitrucin (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 28 Sep 2006 Status change
- 26 Aug 2005 New trial record.